Several rare anaplastic lymphoma kinase (ALK) fusions have been identified in patients with non-small cell lung cancer (NSCLC); however, their treatment is not currently uniform. alectinib has been commonly used to treat rare ALK fusions in patients with NSCLC. This is the first study to report the occurrence of a uridine diphosphate-glucose pyrophosphorylase 2 (UGP2)-ALK fusion in a patient with NSCLC. The patient, who was hospitalized because of shortness of breath lasting 20 days, showed hydrothorax of the left lung under a computerized tomography chest scan. Pathological histology revealed lung adenocarcinoma in the patient. The UGP2-ALK mutation was found by next-generation sequencing. Subsequently, the patient was administered alectinib, and thereafter, the tumor lesion was observed to gradually shrink over the follow-up period. Progression-free survival reached 10 months as of the follow-up date, with no adverse events detected. This case report provides valuable insights into the clinical management of NSCLC patients with UGP2-ALK fusions. Moreover, alectinib is confirmed to be an appropriate therapeutic agent for such patients.

中文翻译：

---

具有罕见 UGP2-ALK 融合蛋白的非小细胞肺癌患者对艾来替尼反应良好：病例报告。

在非小细胞肺癌 (NSCLC) 患者中发现了几种罕见的间变性淋巴瘤激酶 (ALK) 融合；然而，他们的待遇目前并不统一。艾来替尼通常用于治疗 NSCLC 患者中罕见的 ALK 融合。这是第一项报告 NSCLC 患者中发生尿苷二磷酸-葡萄糖焦磷酸化酶 2 (UGP2)-ALK 融合的研究。该患者因持续20天的呼吸困难而入院，胸部计算机断层扫描显示左肺有胸水。病理组织学检查显示患者为肺腺癌。通过二代测序发现UGP2-ALK突变。随后，患者接受了艾乐替尼治疗，随后观察到肿瘤病灶在随访期间逐渐缩小。截至随访日期，无进展生存期达到 10 个月，未检测到不良事件。本病例报告为 UGP2-ALK 融合 NSCLC 患者的临床管理提供了宝贵的见解。此外，艾来替尼被证实是此类患者的合适治疗剂。